發(fā)布時(shí)間：2018-03-06 06:22

  本文選題：胰腺癌　切入點(diǎn)：P2X7受體　出處：《山東大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：目的:胰腺癌作為一種消化道惡性腫瘤,其五年生存率不足5%。胰腺癌早期或術(shù)后發(fā)生的鄰近及遠(yuǎn)處器官轉(zhuǎn)移是導(dǎo)致其手術(shù)切除率低及臨床高死亡率的主要原因,所以研究調(diào)控胰腺癌發(fā)展及侵襲轉(zhuǎn)移的關(guān)鍵分子,對(duì)胰腺癌臨床治療及預(yù)后有重大意義。P2X7受體蛋白作為一種以ATP為配體的門控型離子通道受體,其在多種腫瘤組織中高表達(dá),并參與了腫瘤的發(fā)生、發(fā)展及凋亡等多種病理生理過(guò)程。我們本次的實(shí)驗(yàn)主要探索P2X7受體蛋白在胰腺癌中的表達(dá)及臨床意義,以及其調(diào)節(jié)胰腺癌侵襲遷移的潛在機(jī)制。方法:1.應(yīng)用Western blot實(shí)驗(yàn)和qRT-PCR實(shí)驗(yàn)分析人胰腺癌組織、癌旁組織標(biāo)本中P2X7受體蛋白的表達(dá)情況,并應(yīng)用免疫組織化學(xué)方法分析人胰腺癌組織中P2X7受體蛋白的表達(dá)與胰腺癌臨床病理特點(diǎn)之間的關(guān)系。2.選取正常胰腺細(xì)胞系HPDE6-C7及常見胰腺癌細(xì)胞系SW1990、PANC-1、BxPC-3、MiaPaCa-2及PANC02.03,應(yīng)用Western blot實(shí)驗(yàn)和細(xì)胞免疫熒光實(shí)驗(yàn)檢測(cè)上述細(xì)胞系中P2X7受體蛋白的表達(dá)情況;并篩選出P2X7受體蛋白高表達(dá)的胰腺癌細(xì)胞株,分別設(shè)置對(duì)照組,P2X7受體激動(dòng)劑BzATP(2000μM)處理組,P2X7 受體激動(dòng)劑 BzATP(200μM)+抑制劑 A740003(20μM)處理組,應(yīng)用 Transwell實(shí)驗(yàn)、細(xì)胞劃痕實(shí)驗(yàn)檢測(cè)上述處理后所選細(xì)胞株侵襲遷移能力變化。3.為進(jìn)一步探索P2X7受體蛋白對(duì)胰腺癌細(xì)胞侵襲遷移的潛在機(jī)制,選取P2X7受體蛋白高表達(dá)細(xì)胞株,分別設(shè)置對(duì)照組,P2X7受體激動(dòng)劑BzATP(200μM)處理組,P2X7受體激動(dòng)劑BzATP(2000μM)+抑制劑A740003(20μM)處理組,應(yīng)用Western blot實(shí)驗(yàn)檢測(cè)上述處理后該細(xì)胞株中侵襲遷移相關(guān)蛋白MMP2、MMP9、E-cadherin、Vimentin的表達(dá)情況和對(duì)AKT信號(hào)通路關(guān)鍵蛋白AKT蛋白磷酸化激活的影響。結(jié)果:1.Western blot實(shí)驗(yàn)和qRT-PCR實(shí)驗(yàn)結(jié)果顯示P2X7受體蛋白在胰腺癌組織中高表達(dá),在癌旁組織中低表達(dá);且P2X7受體蛋白表達(dá)水平與胰腺癌的臨床腫瘤分化程度(低分化)及淋巴結(jié)轉(zhuǎn)移呈顯著性相關(guān)(P0.05)。2.Western blot實(shí)驗(yàn)和細(xì)胞免疫熒光實(shí)驗(yàn)結(jié)果顯示P2X7受體在胰腺癌細(xì)胞中高表達(dá),并且選取P2X7受體高表達(dá)的PANC-1細(xì)胞進(jìn)行Transwell實(shí)驗(yàn)、細(xì)胞劃痕實(shí)驗(yàn)結(jié)果顯示,P2X7受體蛋白的激活可促進(jìn)PANC-1細(xì)胞的侵襲遷移。3.免疫印跡實(shí)驗(yàn)結(jié)果顯示,PANC-1細(xì)胞中P2X7受體蛋白激活后,可下調(diào)E-cadherin蛋白表達(dá),上調(diào)Vimentin、MMP2、MMP9蛋白的表達(dá),且使pAKT蛋白的表達(dá)升高且呈時(shí)間依賴性。結(jié)論:1.P2X7受體蛋白在胰腺癌中高表達(dá),并與胰腺癌的分化程度及淋巴結(jié)轉(zhuǎn)移顯著相關(guān)。2.P2X7受體蛋可能通過(guò)AKT信號(hào)通路調(diào)節(jié)E-cadherin、Vimentin、MMP2、MMP9蛋白的表達(dá)進(jìn)而影響胰腺癌的侵襲及遷移。意義:1.研究了 P2X7受體蛋白與胰腺癌臨床病理特征之間的關(guān)系,為進(jìn)一步探索P2X7受體蛋白在胰腺癌發(fā)展中的作用提供相關(guān)的實(shí)驗(yàn)理論依據(jù)。2.P2X7受體蛋白可介導(dǎo)胰腺癌的侵襲及遷移,為胰腺癌的分子靶向治療研究提供了一個(gè)潛在的的靶點(diǎn)。
[Abstract]:Objective: as a malignant tumor of digestive tract, the 5-year survival rate of pancreatic cancer is less than 5 years. The metastasis of adjacent and distant organs in the early stage or after operation of pancreatic cancer is the main cause of low resection rate and high clinical mortality. Therefore, the study of key molecules regulating the development, invasion and metastasis of pancreatic cancer is of great significance for the clinical treatment and prognosis of pancreatic cancer. P2X7 receptor protein, as a gated ion channel receptor with ATP as a ligand, is highly expressed in various tumor tissues. Our experiment mainly explored the expression and clinical significance of P2X7 receptor protein in pancreatic cancer. Methods: 1. The expression of P2X7 receptor protein in human pancreatic carcinoma tissues and adjacent tissues was analyzed by Western blot assay and qRT-PCR assay. The relationship between the expression of P2X7 receptor protein and the clinicopathological characteristics of pancreatic carcinoma was analyzed by immunohistochemical method. 2.The normal pancreatic cell line HPDE6-C7, the common pancreatic cancer cell lines SW1990, PANC-1, BxPC-3, MiaPaCa-2 and PANC02.03were selected, and the Western blot was applied to analyze the relationship between the expression of P2X7 receptor protein and the clinicopathological characteristics of pancreatic carcinoma. The expression of P2X7 receptor protein in the above cell lines was detected by immunofluorescence assay. A pancreatic cancer cell line with high expression of P2X7 receptor protein was screened. The control group treated with P2X7 receptor agonist BzATP(2000 渭 M was treated with P2X7 receptor agonist BzATP(200 渭 M (A740003 渭 M), and the treatment group was treated with Transwell. In order to further explore the potential mechanism of P2X7 receptor protein on invasion and migration of pancreatic cancer cells, a cell line with high expression of P2X7 receptor protein was selected. The control group treated with P2X7 receptor agonist BzATP(200 渭 M and the P2X7 agonist BzATP(2000 渭 M inhibitor A740003 (20 渭 M) were treated with P2X7 receptor agonist A740003 (20 渭 M). Western blot assay was used to detect the expression of invasion and migration associated protein MMP2MMP9 E-cadherin vimentin and its effect on the activation of phosphorylation of AKT protein, a key protein in the AKT signaling pathway. Results 1. The results of Western blot and qRT-PCR experiments showed P2X7. The receptor protein is highly expressed in pancreatic carcinoma. Low expression in paracancerous tissues; The expression of P2X7 receptor protein was significantly correlated with the clinical differentiation (low differentiation) and lymph node metastasis of pancreatic carcinoma. The results of Western blot assay and cellular immunofluorescence assay showed that P2X7 receptor was highly expressed in pancreatic cancer cells. The results of Transwell assay showed that the activation of P2X7 receptor protein could promote the invasion and migration of PANC-1 cells. Western blot showed that P2X7 receptor protein was activated in PANC-1 cells. It can down-regulate the expression of E-cadherin protein, up-regulate the expression of VimentintMMP2MMP9 protein, and increase the expression of pAKT protein in a time-dependent manner. Conclusion: 1. P2X7 receptor protein is highly expressed in pancreatic carcinoma. P2X7 receptor egg may regulate the expression of E-cadherin Vimentinnus MMP2MMP9 protein through AKT signaling pathway, and then affect the invasion and migration of pancreatic carcinoma. Significance: 1. To study P2X7 receptor protein and pancreatic pancreas. The relationship between clinicopathological features of cancer, In order to further explore the role of P2X7 receptor protein in the development of pancreatic cancer to provide relevant experimental theoretical basis .2.P2X7 receptor protein can mediate the invasion and migration of pancreatic cancer, which provides a potential target for the molecular targeted therapy of pancreatic cancer.
【學(xué)位授予單位】：山東大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R735.9

【相似文獻(xiàn)】

相關(guān)期刊論文 前6條

1 謝斌華;彭勇;陳勇;張順;鄔秀娣;張振;黃嫻倩;季蘊(yùn)辛;禹海航;;原發(fā)性干燥綜合征外周血單個(gè)核細(xì)胞P2X7受體表達(dá)及其與焦慮、抑郁的相關(guān)性[J];中華臨床免疫和變態(tài)反應(yīng)雜志;2013年03期

2 張秀軍,鄭國(guó)光,馬小彤,林永敏,宋玉華,吳克復(fù);不同誘導(dǎo)因子對(duì)人外周血單個(gè)核細(xì)胞P2X7受體表達(dá)的作用(英文)[J];生理學(xué)報(bào);2005年02期

3 王麗雁;蔡文琴;陳鵬慧;;P2X7受體在OPCs缺氧缺血性損傷中作用的初步研究[J];重慶醫(yī)學(xué);2010年21期

4 程鵬;王東軍;;P2x7受體在癲癇中的作用[J];海南醫(yī)學(xué);2012年04期

5 劉紅亮;戴體俊;;P2X7受體介導(dǎo)異丙酚對(duì)缺氧海馬突觸前膜谷氨酸Ca~(2+)依賴性釋放的抑制作用[J];中國(guó)藥理學(xué)通報(bào);2010年09期

6 顧藝;肖婧;孫琳;焦偉偉;馮衛(wèi)星;吳喜蓉;申阿東;;P2X7基因多態(tài)性與結(jié)核病易感性的關(guān)聯(lián)性研究——Meta分析[J];標(biāo)記免疫分析與臨床;2010年02期

相關(guān)會(huì)議論文 前2條

1 尹波;褚克曇;彭國(guó)平;羅本燕;;P2X7受體在全腦缺血再灌注損傷中的作用研究[A];2011年浙江省神經(jīng)病學(xué)學(xué)術(shù)年會(huì)論文匯編[C];2011年

2 褚克曇;尹波;彭國(guó)平;羅本燕;;P2X7受體在全腦缺血再灌注損傷后海馬炎癥中的作用研究[A];2011年浙江省神經(jīng)病學(xué)學(xué)術(shù)年會(huì)論文匯編[C];2011年

相關(guān)博士學(xué)位論文 前1條

1 紀(jì)瑞華;P2X7受體在脊髓缺血再灌注損傷中的作用研究[D];第二軍醫(yī)大學(xué);2012年

相關(guān)碩士學(xué)位論文 前5條

1 蔣梅玉;衰老和脂多糖對(duì)小鼠眼球P2X7受體及其變異體表達(dá)的影響[D];廣西醫(yī)科大學(xué);2016年

2 孟雙平;P2X7受體在結(jié)腸炎相關(guān)性結(jié)腸癌進(jìn)展過(guò)程中的作用及機(jī)制研究[D];第二軍醫(yī)大學(xué);2016年

3 王勇;P2X7受體在胰腺癌中的表達(dá)及其對(duì)侵襲遷移影響的實(shí)驗(yàn)研究[D];山東大學(xué);2017年

4 謝斌華;原發(fā)性干燥綜合征外周血單個(gè)核細(xì)胞P2X7受體表達(dá)及其與焦慮、抑郁的相關(guān)性[D];寧波大學(xué);2013年

5 羅鳳燕;P2X7受體在葡聚糖硫酸鈉誘導(dǎo)的小鼠急性結(jié)腸炎發(fā)病中的作用及機(jī)制研究[D];南昌大學(xué);2014年

，

本文編號(hào)：1573678